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Background—There are limited data on the epidemiology of respiratory syncytial virus (RSV) 
illness in HIV-infected adults or the elderly in Africa. We studied the epidemiology of RSV-
associated severe acute respiratory illness (SARI) hospitalizations in adults in South Africa from 
2009 through 2013.
Methods—Individuals admitted to sentinel surveillance hospitals were investigated by 
respiratory tract swabs for RSV, using a multiplex real-time polymerase chain reaction assay. The 
incidence of RSV-associated SARI was calculated for the one site with population denominators.
Results—Of 7796 participants investigated, 329 (4%) tested positive for RSV. On multivariable 
analysis, HIV-infected individuals with RSV-associated SARI had greater odds of being in the age 
groups 18–44 and 45–64 years (odd ratios (OR) 26.3; 95% confidence interval (CI) 6.2–112.1 and 
OR 11.4; 95% CI 2.6–50.0) compared with those ≥65 years and being female (OR 2.7; 95% CI 
1.4–5.4). The relative risk of hospitalization with RSV-associated SARI was 12–18 times higher in 
HIV infected individual compared to that of HIV-uninfected.
Conclusion—The incidence of RSV-associated SARI was higher in HIV-infected individuals 
and those aged 65 years and older. Further studies are warranted to describe the disease association 
of RSV detected in adults with SARI.
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Introduction
There are limited data on the epidemiology of respiratory syncytial virus (RSV) infection in 
adults and older children in high HIV prevalence settings like South Africa. In high income 
countries with a lower HIV burden, the burden of hospitalization with RSV in the elderly 
has been described as similar to that of influenza.1–4 Also, RSV infection has been reported 
to be more severe in the elderly, people living in long term care facilities, immune 
compromised individuals (specifically those with stem cell and lung transplants) and 
individuals receiving chemotherapy.4–6 Other risk factors in adults include underlying 
cardiac disease and chronic respiratory illness.7 In a prospective hospital-based surveillance 
programme in the United States amongst elderly (≥65 years), RSV was identified in 11% of 
pneumonia episodes, 11% of chronic obstructive pulmonary disease episodes, 5% of 
congestive heart failure events and 7% of asthma cases.8
In South Africa the highest HIV prevalence occurs among adults aged 15–49 years and was 
17% in 2012.9 Of the HIV-infected adults eligible for antiretroviral treatment on the 
guidelines applicable during the study period (CD4+ T cell count <350/mm3) it was 
estimated that 29% in 2009 and 52% in 2011 had initiated treatment.10
We aimed to describe the effects of HIV on the incidence, epidemiology and clinical 
characteristics of RSV-associated severe acute respiratory illness in adults in South Africa.
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Methods
Description of the surveillance programme and study population
The Severe Acute Respiratory Illness (SARI), prospective hospital-based sentinel 
surveillance programme, was implemented in February 2009. We include data from 
February 2009 through December 2013. The programme is active in four of the nine 
provinces of South Africa including at Chris Hani-Baragwanath Academic Hospital 
(CHBAH) in an urban area of Gauteng Province, Edendale Hospital in a peri-urban area of 
KwaZulu-Natal Province, Matikwana and Mapulaneng Hospitals in a rural area of 
Mpumalanga Province and Klerksdorp and Tshepong Hospitals in a periurban area of the 
Northwest Province (added in June 2010).
Study procedures
Individuals admitted to sentinel hospitals within seven days of onset of symptoms were 
screened for SARI per World Health Organization (WHO) case definition.11 The criteria 
included: (1) documented sudden onset of fever (>38 °C) or patient-reported fever, (2) cough 
or sore throat, and (3) shortness of breath, or difficulty breathing. Only patients with 
symptom duration of 7 days or less were included in this analysis. Admission criteria and 
inhospital treatment protocols (including intensive care (ICU) admission) were at the 
discretion of the attending physician. There is limited access to ICU beds in South African 
public hospitals, protocols for ICU admission vary between hospitals and are based on the 
number of beds available. Oxygen therapy is however, widely available in the general ward 
setting. All patients admitted (those who spent a night in hospital) from Monday through 
Friday were eligible for enrolment and enrolled if the WHO case definition was met. At 
CHBAH, due to the large numbers of subjects and limited resources, enrolment was limited 
to two of every five working days per week; the selected days varied systematically. Logs 
were maintained for the total numbers of hospitalized individuals (including those enrolled 
over weekends and public holidays) who met the study case definitions and of those enrolled 
by the study-staff. Structured case investigation forms were completed for demographic and 
clinical information. Enrolled subjects were followed up until death, out-referral to a step-
down facility or discharge. A nasopharyngeal (NP) and an oropharyngeal (OP) swab were 
collected for respiratory virus testing. Blood samples were collected for pneumococcal lytA 
polymerase chain reaction (PCR) testing and anonymous linked HIV testing by HIV-ELISA 
was undertaken for those subjects among whom HIV-testing was not undertaken by the 
attending physician. The collection of blood for bacterial culture and sputum for 
Mycobacterium tuberculosis (TB) testing was done at the discretion of the attending 
physicians.
Laboratory methods
Upper respiratory secretion samples (combined NP and OP) were transported in a single vial 
of viral transport medium at 4–8 °C to reach the National Institute for Communicable 
Diseases (NICD) within 72 h of collection. Any storage of sample at the surveillance site 
was in a temperature regulated refrigerator (4–8 °C). Respiratory specimens were tested by 
multiplex real-time reverse-transcription PCR (RT PCR) assay for 10 respiratory viruses 
(respiratory syncytial virus; influenza A and B viruses, parainfluenza virus 1, 2 and 3; 
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enterovirus; human metapneumovirus; adenovirus and rhinovirus) as detailed elsewhere.12 
Streptococcus pneumoniae was identified by quantitative real-time PCR detecting the lytA 
gene from whole blood specimens.13
Evaluation of HIV infection status
HIV testing was requested by admitting physicians when clinically indicated according to 
standard practice. This included HIV enzyme-linked immunosorbent assay (ELISA) testing 
with confirmation by ELISA on a second specimen. In addition, for consenting patients, an 
anonymized linked dried blood spot specimen was taken for determination of HIV status by 
ELISA.
Definitions
Underlying chronic medical conditions included asthma, chronic lung disease, chronic heart 
disease, liver disease, renal disease, diabetes mellitus, immune-compromising conditions 
other than HIV infection based on solicitation from the individual and medical-record 
review.
Calculation of incidence
The incidence of RSV-associated SARI hospitalizations was estimated for Soweto 
(CHBAH) – the only site for which population denominator data were available. CHBAH is 
the only public hospital serving a community of about 1 million (persons aged ≥ 18 years in 
2012). We estimated the incidence of RSV-associated SARI hospitalizations per 100 000 
population, the numerator was calculated using the number of RSV-positive SARI 
hospitalizations and adjusting for non-enrolment (refusal to participate, non-enrolment 
during weekends and limited sampling of two of the five adult wards) and the dominator 
being the mid-year population for each of the age groups. All individuals hospitalized with 
SARI during the study period were logged and this was used to estimate the number of 
SARI cases not enrolled during the study period. The actual number of RSV-associated 
cases was then multiplied by the adjustment factor. Adjustment factors were calculated for 
each age group (18–44 years, 45–64 years and ≥65 years). Incidence calculations using the 
adjusted number of cases, stratified by age group and HIV status and divided by the mid-
year age specific population estimates for each year.14 The HIV prevalence in the study 
population, by age group, was estimated from the projections of the Actuarial Society of 
South Africa (ASSA) AIDS and Demographic model9 and used to impute denominators for 
numbers of HIV-infected individuals in the population. Confidence intervals for incidence 
estimates were calculated using the Poisson distribution. Age-specific and overall age-
adjusted incidence of RSV-associated SARI in HIV-infected and HIV-uninfected persons 
was determined using log-binomial regression. Incidence is calculated for the complete 
years (surveillance started late in 2009) of surveillance 2010, 2011 and 2012. In 2013 
enrolment was down-scaled at this site and so incidence calculations were not done for this 
year.
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Seasonality
A description of the seasonality of RSV-associated SARI and total SARI hospitalizations 
was done by calculating the detection rate of RSV (number of cases of RSV divided by total 
SARI cases) by month for each year of the study.
Statistical analysis
A descriptive analysis was conducted for demographic and clinical factors associated with 
SARI in those individuals with RSV-associated SARI. A separate univariate and 
multivariable analysis by logistic regression was conducted to compare HIV-infected and 
HIV-uninfected patients with RSV-associated SARI, in which all available information on 
cases were used. A sensitivity analysis was conducted to explore the effect of missing HIV 
results on our findings. We repeated the analysis in two scenarios, first considering all those 
with missing result as HIV-uninfected and secondly considering all those with missing 
results as HIV-infected. Age group, duration of hospitalization, duration of symptoms and 
year were defined as categorical variables in multiple levels. All other variables were defined 
as the presence or absence of the attribute excluding missing data. Multivariate models were 
explored for univariate association with p value of <0.1. Statistical significance was decided 
on p value of 0.05 or less. Data were analysed using Stata® version 12 (StataCorp Limited, 
College Station, Texas, USA).
Ethical considerations
The protocol was approved by the Research Ethics Committees of the Universities of the 
Witwatersrand and KwaZulu-Natal. This surveillance was deemed non-research by the 
United States of America’s Centers for Disease Control and Prevention (CDC) and did not 
need human subjects review by that institution. Written informed consent was obtained from 
all participants.
Results
From February 2009 through December 2013, 7872 individuals aged 18 years and older 
were enrolled who met the case definition of SARI. The majority of subjects were enrolled 
at the CHBAH (68%; 5380) and were female (4901; 62%). HIV results were available for 
89% (7039/7872) of enrolled subjects, with an overall sero-positivity of 76% (5321/7039). 
Only 46% (1673/3657) of individuals known to be HIV-infected at enrolment were on 
antiretroviral treatment (ART) at the time of admission.
Demographic and clinical characteristics of patients with RSV-associated SARI
Of the 7872 enrollees, 7796 (99%) were tested for RSV which was detected in 4% of cases 
(329). The detection rate in HIV-infected 228/5297 (4%) and HIV-uninfected patients 
57/1708 (3%) was similar (p = 0.079). The overall detection rate of RSV was similar across 
all age groups (18–44 years: 4%, 217/5129; 45–64 years: 4%, 93/2138; ≥65 years: 4%, 
19/529, p = 0.738). The detection rate of RSV varied by year and was 2% in 2009 (20/1215); 
4% (84/2004) in 2010; 4% (72/1981) in 2011, 6% (119/1861) in 2012 and 5% (34/735) in 
2013 (p < 0.001). Other demographic and clinical characteristics of RSV-associated 
compared to RSV-negative SARI cases were similar (data not shown). The median duration 
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of symptoms prior to hospitalization was 4 days (range 0–7). S. pneumoniae was detected in 
8% (25/304) of RSV-associated cases. In 64% (209/329) of cases, RSV was the only virus 
detected on PCR. The common co-infections with RSV included rhinovirus (16%; 52/329) 
and adenovirus (15%; 50/328). Influenza virus was detected in (6%; 21/329) of cases (Table 
1).
The median duration of hospitalization for RSV-associated SARI cases was 6 days (range 1–
41), 48% (155/329) of subjects required supplemental oxygen therapy and 1% (2/325) 
required mechanical ventilation. The overall case fatality ratio (CFR) for RSV-associated 
cases was 9% (29/314) (Table 1).
HIV-infection and RSV-associated SARI
The overall prevalence of HIV among RSV-associated cases was 80% (228/285). The HIV 
prevalence by age group was 87% in 18–44 years (166/228), 73% in 45–64 years (59/81) 
and 21% in those ≥ 65 years (3/14). HIV-uninfected individuals were at greater odds of 
having an underlying illness (excluding HIV and tuberculosis) than HIV-infected individuals 
(OR 4.1, 95% CI 1.9–8.9). The case fatality ratio in HIV-infected individuals (9%; 21/218) 
was similar to HIV-uninfected individuals with RSV-associated SARI (9%; 5/53), p = 0.965 
(Table 2). On multivariable analysis age group (18–44 years: adjusted odds ratio (aOR) 26.3; 
95% CI 6.2–112.1 and 45–64 years: aOR 11.4; 95% CI 2.6–50.0), female sex (aOR 2.7; 
95% CI 1.4–5.4), underlying illness (excluding HIV and tuberculosis) (aOR 0.3; 95% CI 
0.1–0.7) and longer symptom duration prior to hospitalization (2 to <5 days aOR 4.4 (95% 
CI 1.7–11.0) and 5–7 days aOR 4.2 (95% CI 1.6–10.4) compared to <2 days) remained 
associated with HIV infection in patients with RSV-associated SARI (Table 2). In the 
sensitivity analyses all associations remained significant (data not shown).
Incidence of hospitalization in HIV-infected and HIV-uninfected individuals with RSV-
associated SARI
The overall incidence (per 100 000 population) of RSV-associated SARI was 30 (95% CI 
26–34) in 2010, 22 (95% CI 19–25) in 2011 and 30 (95% CI 27–34) in 2012. The incidence 
of RSV-associated SARI was higher in HIV-infected individuals compared to HIV-
uninfected individuals for all age groups (Table 3). HIV-infected individuals with RSV-
associated SARI had a higher incidence of hospitalization across all age groups and in an 
age adjusted model in each year studied (2010; aRR 18 (95% CI 13–24), 2011; aRR 12 
(95% CI 8–16), 2012; aRR 14 (95% CI 11–19)) (Table 3).
Elderly patients with RSV-associated SARI
Among the elderly (≥65 years age), 4% (19/529) tested positive for RSV. Patients aged ≥65 
with RSV infection years had a 6 times greater odds of having an underlying illness (other 
than HIV and TB) as compared to patients aged 45–64 years (OR 6.8, 95% CI 2.4–19.7) and 
twice the odds of those aged 18–44 years (OR 2.4 95% CI 1.8–5.1). Although most of the 
deaths occurred in the 18–44 year (18/207, 9%) and 45–64 year age groups (7/89, 8%), the 
case fatality ratio was highest in the ≥65 years age group (4/18, 22%), p= 0.143. Three 
quarters of the patients aged ≥65 years who died were HIV-infected (3/4: 75%) and 50% 
(2/4) had an underlying illness (other than HIV and TB). The elderly (both HIV-infected and 
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HIV-uninfected individuals) experienced the highest incidence of hospitalization with RSV-
associated SARI across all three years (Table 3).
Seasonality
Although RSV was detected all year round in South Africa, a small seasonal peak was seen 
between February and June, in most years the detection rate was more than 20% during 
these months. There was considerable variation between the years of study (Fig. 1). There 
was no marked seasonal variation in the total number of SARI hospitalizations (data not 
shown).
Discussion
We describe a high incidence of hospitalization in HIV-infected adults with RSV-associated 
SARI; however, these individuals did not have more severe outcomes with respect to 
prolonged hospitalization and mortality when compared to HIV-uninfected individuals. 
Similar to other published data, elderly patients (≥65 years) had a higher incidence of RSV-
associated SARI hospitalization, greater odds of having underlying illnesses and trended to 
having higher CFR than younger patients.3–5
Although immunocompromised states are considered a risk factor for RSV-associated SARI, 
data specific to HIV-associated immunocompromised individuals are confined to a number 
of case reports of severe RSV-associated SARI in HIV-infected individuals.15–19 These 
authors describe a clinical syndrome similar to that of Pneumocystis jirovecii pneumonia 
and one patient developed acute adult respiratory distress syndrome. Available evidence 
suggests that the immune response to RSV infection requires both humoural and cellular 
elements, specifically CD4+ and CD8+ T cells which are critical in terminating an acute 
RSV infection. Antibodies may provide protection against re-infection, although this 
response may wane with time, meaning individuals over time will revert to being susceptible 
to re-infection.18 Studies in children with defective T cell function demonstrate prolonged 
viral shedding and increased disease severity.20,21 CD4+ T cells are important for the 
production of interleukin and cytokines. Evidence is available for the link between lack of 
these cytokines and disease severity,22 though other studies have failed to show this 
association.23–26 Conversely there is also evidence to suggest cellular responses may 
contribute to disease. Histological studies indicate that RSV infection is associated with 
extensive obstruction of the small airways caused by inflammatory cells, cellular debris and 
oedema caused by peri-bronchiolar lymphoid aggregate; these inflammatory cells include 
neutrophils, CD4+ and CD8+ T cells.26 Individuals with compromise to their immune 
systems, like HIV-infected adults, may be more at risk of severe infection but the role of a 
decreased immune response may need further description.
HIV infection is often associated with increased susceptibility to diseases due to intracellular 
pathogens, such as P. jirovecii, M. tuberculosis, Mycoplasma avium-intracellulare (MAI) 
infection, Legionella and intracellular viruses such as cytomegalovirus (CMV). Data are not 
presented for these pathogens as co-infections for this analysis. One important potential co-
infection common in HIV-infected individuals was tested for in our study and the proportion 
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of cases with S. pneumoniae co-infection is similar to the proportion of S. pneumoniae co-
infection all cause SARI infections admission in our study setting.27
Sensitive PCR technology for the detection of respiratory virus from samples taken from the 
upper airways poses the question of disease association or viral colonization. In a population 
based study in Kenya; Bigogo et al., found a high detection rate of RSV in individuals older 
than 5 years of age presenting with SARI but found similar, although not significant, 
detection rates of RSV in controls (OR 1.22 (95% CI: 0.82–1.83)).28 Conversely Feiken et 
al. describe disease association with RSV detection by comparing healthy controls to those 
admitted to hospital with acute respiratory illness (OR 2.9 (1.3–6.6)), across all age 
groups.29 A preliminary analysis in our setting comparing healthy controls (people attending 
outpatient clinics with no respiratory illness in 14 days prior to visit) to SARI cases admitted 
to hospital fitting the same clinical case definition as those in this study suggests that HIV-
infected individuals with RSV are at increased odds of hospitalization (OR 4.2 (95% CI: 
1.2–14.9) in the 25–54 year age group and OR 7.4 (95%CI: 1.2–46.8) in those older than 55 
years).30
There are varying reports of the incidence of RSV-associated lower respiratory tract 
infection or RSV-associated SARI. These range from 2.9 to 130 per 100 000 population. 
Some of the differences in reported incidence may be explained by the different definitions 
of respiratory illness, whether by clinical case definition, or radiological confirmed 
pneumonia, geographic local and different reporting of age group. However, in all 
population-based studies across developing and developed worlds, similar trends to those in 
our study are described with incidence rates increasing in the older age groups.1,2,31–35
The specific case fatality ratio for RSV-associated SARI described in this analysis is similar 
to the all cause SARI case fatality ratio described in our setting.36 Modelling done in South 
Africa describes excess mortality associated with the RSV season in South Africa among 
adults aged 25–44 years (high HIV prevalence age group).37 The relative risk of death in 
HIV-infected compared to HIV-uninfected in this age group was RR 81.7 in all cause death 
data and RR 73.4 in pneumonia and influenza deaths data however excess mortality in was 
not seen in the RSV season in elderly patients. In a similar modelling study done in our 
setting, excess hospitalizations were described during the RSV season in the <5 year age 
group but not in individuals older than 20 years of age.38 This study was conducted in a 
medically insured population which may not have similar characteristics to the study 
population in this study. Specific studies to address risk factors for hospitalization with RSV-
associated SARI and the attributable fraction of disease would be of value to further describe 
the disease association in RSV-associated SARI in adults.
In this study of hospitalized adults in South Africa, RSV was detected all year round with an 
increase in detection from February to June in most years. When we compare these data to 
data from hospitalized children at the same sites, the RSV season appeared more marked in 
children aged <5 years. In children during the seasonal peaks the detection rate of RSV in 
children hospitalized with SARI reached 60% in some years.39 The peak in this analysis was 
31% in week 10 of 2013.
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There were a number of limitations to this study: (1) Data on underlying illnesses were 
collected from a structured interview which may have been subject to recall bias; (2) We 
were not able to describe the degree of immune compromise in the elderly or the general 
condition of the elderly; (3) Opportunistic infections such a P. jirovecii and TB were not 
reported in this study period which does not allow the description of the association between 
RSV-positive SARI and these pathogens in HIV-infected individuals; (4) Our study was 
limited by the unavailability or paucity of data on HIV indices such as ART. Furthermore, 
we did not clinically stage patients with HIV and it is also possible that admission criteria 
for known HIV-infected patients may differ by attending physician and hospital; (5) One of 
the most common reasons for non-enrolment was that the patient was too ill to consent; this 
may bias our estimation of severity; Previously published data from the same surveillance 
programme found a 10% non-enrolment rate into the surveillance programme, of whom 
50% were too ill to consent and 11% refused to participate with the remainder having a 
variety of reasons for refusal.40 (6) Our confidence interval may not account for the 
variability in numbers due to enrolment strategies and so may be imprecise; (7) Lastly 
population denominators were only available for one large urban hospital site, making it 
difficult to generalize the findings to other sites in the country; (8) The adjustment factors 
used in our incidence calculation are based on a number of assumptions and this uncertainty 
in not captured in the confidence intervals for our estimates of incidence; (9) It is possible 
that health seeking behaviour is different by age and HIV status which could affect our 
estimation of disease incidence; (10) The true burden of RSV-associated respiratory tract 
infection is not complete without an estimation of outpatient burden, these data are not as yet 
published in our setting.
Conclusion
RSV-associated SARI is commonly detected in HIV-infected individuals. In the elderly RSV 
infection is associated with severe illness. An RSV vaccine if available should target high 
risk groups such as the elderly (≥65 years) and possibly HIV-infected individuals to prevent 
hospitalization with RSV-associated SARI in this setting.
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Figure 1. 
Detection rate of RSV in patients admitted with SARI by month and year, South Africa 2009 
to 2013.
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Table 1
Demographic and clinical characteristic of individuals ≥18 years admitted with RSV-associated severe acute 
respiratory tract infection (SARI), South Africa 2009 to 2013.
Characteristics RSV-associated LRTI
n/N (%)
Age group (years) 18 to 44 217/329 (66)
45 to 64 93/329 (28)
≥65 19/329 (6)
Female 209/329 (64)
Black African race 314/329 (95)
Presenting symptoms and underlying medical conditions
Duration of symptoms prior to admission (days), median (range) 4 (0–7)
HIV infectiona 228/285 (80)
CD 4 + T cell count in those HIV infected <200 cell/mm3 58/90 (64)
>200 cell/mm3 32/90 (36)
Any underlying medical condition excluding HIV and TBb 40/329 (12)
Infectious agents identified
RSV single virus infection 224/329 (68)
Pneumococcal infectionc 25/304 (8)
Started on tuberculosis treatment during admission 32/324 (10)
Influenza (any type) 21/3296
Adenovirus 50/32815
Enterovirus 7/3292
Rhinovirus 52/32916
Human metapneumovirus 4/3291
Parainfluenza virus 1 3/3291
Parainfluenza virus 2 2/3291
Parainfluenza virus 3 5/3292
Clinical course
Oxygen required 155/329 (48)
Admitted/transferred to intensive care unit 2/325 (1)
Mechanical ventilation 2/325 (1)
Duration of hospitalisation (days) median (range) 6 (1–41)
Duration of hospitalization <2 days 13/317 (4)
2–7 days 195/317 (62)
8+ days 109/317 (34)
Case-fatality ratio 29/314 (9)
a
HIV – human immunodeficiency virus.
bAsthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), 
liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, immunocompromising 
conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological disease 
(cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for 
which the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.
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c
Presence of Streptococcus pneumoniae infection identified by lyt A PCR or on blood culture.
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